You are here

Article Text

Article menu
Download PDFPDF
Extended report
CCL3L1 gene-containing segmental duplications and polymorphisms in CCR5 affect risk of systemic lupus erythaematosus
  1. M Mamtani1,
  2. B Rovin2,
  3. R Brey3,
  4. J F Camargo1,
  5. H Kulkarni1,
  6. M Herrera1,
  7. P Correa4,
  8. S Holliday5,
  9. J-M Anaya4,6,
  10. S K Ahuja1,7
  1. 1
    The Veterans Administration Center for AIDS and HIV-1 Infection, South Texas Veterans Health Care System and Department of Medicine, University of Texas Health Science Center at San Antonio, Texas, USA
  2. 2
    The Ohio State University College of Medicine and Public Health and Davis Heart and Lung Research Institute, Columbus, Ohio, USA
  3. 3
    Department of Neurology, University of Texas Health Science Center at San Antonio, Texas, USA
  4. 4
    Cellular Biology and Immunogenetics Unit, Corporacion para Investigaciones Biologicas, Medellin, Colombia
  5. 5
    Psychology Service, South Texas Veterans Health Care System, San Antonio, Texas, USA
  6. 6
    School of Medicine, Universidad del Rosario, Bogota, Colombia
  7. 7
    Departments of Microbiology and Immunology, and Biochemistry, University of Texas Health Science Center, San Antonio, Texas, USA
  1. S K Ahuja, Veterans Administration Center for AIDS and HIV infection, University of Texas Health Science Center, 7703 Floyd Curl Drive, Room 5.009R, San Antonio, Texas, 78229-7870, USA; ahujas{at}uthscsa.edu

Abstract

Objectives: There is an enrichment of immune response genes that are subject to copy number variations (CNVs). However, there is limited understanding of their impact on susceptibility to human diseases. CC chemokine ligand 3 like-1 (CCL3L1) is a potent ligand for the HIV coreceptor, CC chemokine receptor 5 (CCR5), and we have demonstrated previously an association between CCL3L1-gene containing segmental duplications and polymorphisms in CCR5 and HIV/AIDS susceptibility. Here, we determined the association between these genetic variations and risk of developing systemic lupus erythaematosus (SLE), differential recruitment of CD3+ and CD68+ leukocytes to the kidney, clinical severity of SLE reflected by autoantibody titres and the risk of renal complications in SLE.

Methods: We genotyped 1084 subjects (469 cases of SLE and 615 matched controls with no autoimmune disease) from three geographically distinct cohorts for variations in CCL3L1 and CCR5.

Results: Deviation from the average copy number of CCL3L1 found in European populations increased the risk of SLE and modified the SLE-influencing effects of CCR5 haplotypes. The CCR5 human haplogroup (HH)E and CCR5-Δ32-bearing HHG*2 haplotypes were associated with an increased risk of developing SLE. An individual’s CCL3L1–CCR5 genotype strongly predicted the overall risk of SLE, high autoantibody titres, and lupus nephritis as well as the differential recruitment of leukocytes in subjects with lupus nephritis. The CCR5 HHE/HHG*2 genotype was associated with the maximal risk of developing SLE.

Conclusion: CCR5 haplotypes HHE and HHG*2 strongly influence the risk of SLE. The copy number of CCL3L1 influences risk of SLE and modifies the SLE-influencing effects associated with CCR5 genotypes. These findings implicate a key role of the CCL3L1–CCR5 axis in the pathogenesis of SLE.

https://doi.org/10.1136/ard.2007.078048

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • ▸ Supplementary note 1 is published online only at http://ard.bmj.com/content/vol67/issue8

    • Funding: This work was supported by the Veterans Administration Center on AIDS and HIV infection of the South Texas Veterans Health Care System and a MERIT (R37046326) and other awards (AI043279 and MH069270) from the NIH and other organisations (Elizabeth Glaser Scientist Award and the Burroughs Wellcome Clinical Scientist Award in Translational Research) to SKA, and the DK55546 award to BHR and the Fernando Chalem Rheumatology Award to J-MA. This work was also supported by NIH grants NS35477 (RB) and M01 RR001346, a shared resources grant to the University of Texas Health Science Center.

    • Competing interests: None.